News from AHA 2024: KRAKEN trial, Muvalaplin, Lp(a)

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
AHA 2024 - Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin – an investigational oral Lp(a) inhibitor – was investigated in patients with elevated Lp(a) levels and high CV risk.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in JAMA
Release date: 19 November 2024

Recommended

Details

Presenters

Overview
AHA 2024 - Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin – an investigational oral Lp(a) inhibitor – was investigated in patients with elevated Lp(a) levels and high CV risk.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in JAMA
Release date: 19 November 2024

Promising results with oral Lp(a) inhibitor in phase 2 trial